Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

View 0 Studies Requested

Browse Lab Results > 2012-0356

Trial Summary

About CDAS Project, PI, Publications: Circulating inflammation markers and risk of lung cancer: A replication study

Datasets


Site: Lung

Inclusion Criteria:

  • Valid Smoking History
  • No Prior History of Lung Cancer
  • Not in 2009-00516 Scarring
  • No Rare Cancer
  • No Self Report/Unconfirmable Lung Cancer in Controls
  • Serum Available
  • Pre-Diagnostic Serum Available
  • Serum Available 1-10 Years Before Diagnosis
  • Cases With Similar Time from Draw to Diagnosis as Cases in 2009-00516

Matching Factors:

  • Gender
  • Age at Randomization (5 year intervals)
  • Calendar Year of Blood Draw (2 year intervals)
  • Study Year of Blood Draw
  • Smoking History
  • Years Since Quit Smoking (<15, 15+)
  • Pack Years Smoked (<30, 30-40, 40-50,50+)

Match Ratio: 1:1 for ever smokers, 3:1 for never smokers

Match Technique: Individual matching only non-cases as controls.

Additional Matching Comments: GWAS controls were rematched to selected controls without a GWAS on all matching factors, as well as race (3 levels) and cancer experience.


Analytes:

  • B-Cell Attracting Chemokine 1
  • Basic Fibroblast Growth Factor
  • C-Reactive Protein
  • Chemokine (C-C Motif) Ligand 13
  • Chemokine (C-C Motif) Ligand 19
  • Chemokine (C-C Motif) Ligand 2
  • Chemokine (C-C Motif) Ligand 20
  • Chemokine (C-C Motif) Ligand 21
  • Chemokine (C-C Motif) Ligand 22
  • Chemokine (C-C Motif) Ligand 27
  • Chemokine (C-C Motif) Ligand 8
  • Chemokine (C-X-C Motif) Ligand 1
  • Chemokine (C-X-C Motif) Ligand 10
  • Chemokine (C-X-C Motif) Ligand 11
  • Chemokine (C-X-C Motif) Ligand 12
  • Chemokine (C-X-C Motif) Ligand 5
  • Chemokine (C-X-C Motif) Ligand 6
  • Chemokine (C-X-C Motif) Ligand 9
  • Eotaxin
  • Eotaxin-2
  • Epidermal Growth Factor
  • Granulocyte-Colony Stimulating Factor
  • Interleukin 1
  • Interleukin 1 Receptor Antagonist
  • Interleukin 16
  • Interleukin 29
  • Interleukin 3
  • Interleukin 33
  • Interleukin 7
  • Interleukin 8
  • Macrophage Inflammatory Protein 1 delta
  • Macrophage inflammatory protein 1 beta
  • Serum Amyloid A
  • Serum Amyloid P
  • Soluble Epidermal Growth Factor Receptor
  • Soluble Interleukin 4 Receptor
  • Soluble Interleukin 6 Receptor
  • Soluble Interleukin 6 beta
  • Soluble Tumor Necrosis Factor Receptor I
  • Soluble Tumor Necrosis Factor Receptor II
  • Stem Cell Factor
  • Thrombopoietin
  • Thymic Stromal Lymphopoietin
  • Thymus and Activation Regulated Chemokine
  • Transforming Growth Factor Alpha
  • Tumor Necrosis Factor Alpha 1
  • Tumor Necrosis Factor Beta
  • Tumor Necrosis Factor Receptor Superfamily, Member 10
  • Vascular Endothelial Growth Factor
  • Vascular endothelial growth factor receptor 2
  • Vascular endothelial growth factor receptor 3

Number of Cases: 526

Number of Controls: 626